Blood stem cell transplantation for breast cancer: New approaches using pre- peri- post-transplant immunotherapy

Expert Opinion on Biological Therapy

Volumn 1, Issue 6, 2001, Pages 1029-1048

  Hinterberger Fischer, Margareta ^a   Hinterberger, Wolfgang ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

breast cancer; cytokine; haematopoietic stem cell transplantation; immunomodulation; immunotherapy; monoclonal antibody; prolactin; vaccine

Indexed keywords

BREAST TUMOR; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; REVIEW;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; SUPPORT, NON-U.S. GOV'T;

EID: 0035514374     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.6.1029     Document Type: Article

References (181)

1. GALE R P, PARK RE, DUBOIS R et al.: Delphi-panel analyis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin. Transplant. (2000) 14:32-41.
2. ROWLINGS PA,WILLIAMS SF, ANTMAN KH et al.: Factors correlated with progression free survival after high dose chemotherapy and hematopietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 282:1335-1343.
3. NIETO Y, CHAMPLIN RE, WINGARD JR et al: Status of high-dose chemotherapy for breast cancer: a review. Biol. Blood Marrow Transplant. (2000) 6:476-495.
4. STADTMAUER EA, O'NEILL A, GOLDSTEIN LJ et al: Conventional dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. N. Engl. J. Med. (2000) 342:1069-1076.
5. BRODOWICZ T, AUERBACH L, ZIELINSKI C: High dose chemotherapy plus hematopoietic stem cell rescue for metastatic breast cancer. N. Engl. J. Med. (2000) 343:439-440.
6. LOTZ J P, CURE H, JANVIER M et al.: Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04. Hematol. Cell Ther. (1999) 41:71-74.
7. CRUMP M, GLUCK S, DOUGLAS S et al.: A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 82.
8. RODENHUIS S, BONTENBAL M, BEEX LVAM et al: Randomized phase III study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 286.
9. GIANNI A, BONADONNA G: Five year results of the randomized clinical trial comparing standard versus high dose myeloablative chemotherapy in the adjuvant treatment of breast cacner with > 3 positive nodes (LN+). 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 80.
10. HORTOBAGY GN, BUZDAR AU, THERIAULT RL et al: Randomized trial of high dose chemotherapy and blood cell autografts for high risk primary breast carcinoma. J. Natl Cancer Inst (2000) 92:225-233.
11. ROCHE HH, POUILLART P, MEYER N et al: Adjuvant high dose chemotherapy improves early outcome for high risk (N>7) breast cancer patients: the Pegase 01 Trial. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 102.
12. PETERS W, ROSNER G, VREDENBURGH J et al: Updated results of a prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: CALGB 9082/SWOG9114/NCIC Ma-13. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 81.
13. KUREBAYASHI JJ: Biological and clinical significance of her2 overexpression in breast cancer. Breast Cancer (2001) 8:45-51.
14. BRAUN S, PANTEL K, MULLER P et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N. Engl J. Med. (2000) 342:525-533.
15. BALLESTER OF, FANG T, WILCOX P et al: New high dose therapy regimens for metastatic breast cancer. Can they improve outcomes? 37th Annual meeting of the American Society of Onclogy (ASCO) (2001). Abstract 1752.
16. HU WW, NEGRIN RS, STOCKERL-GOLDSTEIN et al: Four-cycle high dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. Biol. Blood Marrow Transplan. (2000) 6:58-69.
17. ELIAS AD, RICHARDSON P, AVIGAN D et al: A short course of induction chemotherapy followed by two cycles of high dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant (2001) 27:269-278.
18. FEFER A: Graft versus tumor response. In: Hematopoetic Cell Transplantation. ED Thomas, KG Blume, SJ Forman (Eds.), Blackwell Science, Boston (1999):316-326.
19. UENO NT, RONDON G, MIRZA NQ et al: Allogeneic peripheral blood progenitor cell transplantation for poor risk patients with metastatic breast cancer. J. Clin. Oncol. (1998) 16:986-993.
20. CARELLA AM, CHAMPLIN R, SLAVIN S, MC SWEENEY P, STORB R. Mini allografts: ongoing trials in humans. Bone Marrow Transplant. (2000) 25:345-350.
21. LUZNIK L, ENGSTROM LW, FUCHS EJ, COUZI RJ: Significant antitumor activity of non-myeloablative allogeneic bone marrow transplantation and donor lymphocyte infusion in the treatment of metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 389.
22. BREGNI M, DODERO A, PECCATORI J et al: Graft versus tumor effect in advanced solid tumors following reduced intensity stem cell allografting. 37th Annual meeting of the American Society of Oncolocy (ASCO) (2001). Abstract 45.
23. PORTER DL, CONNORS JM, VAN DEERLIN et al: Graft versus tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J. Clin. Oncol. (1999) 17:1234.
24. HESS AD, THOBURN CJ, CHEN W, HORWITZ LR: Complexity of effector mechanisms in cyclosporine-induced syngeneic graft versus host disease. Biol Blood Marrow Transplant. (2000) 6:13-24.
25. VAN DER WALL E, HORN T, BRIGHT E et al: Autologous graft versus host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br. J. Cancer (2000) 83:1405-1411.
26. NEGRIN RS: Prevention and therapy of relapse after autologous haematopoietic cell transplantation. In: Hematopoetic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999): 1123-1134.
27. GUILLAUME TH, RUBINSTEIN DB, SYMANN M: Immune reconstitution and Immunotherapy after autologous hematopoietic stem cell transplantation. Blood (1998) 92:1471-1490.
28. PORRATA LF, LITZOW MR, MARKOVIC SN: Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin. Proc. (2001) 76:407-412.
29. SHENOY S, MOHANAKUMAR T, TODD G et al: Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. (1999) 23:335-346.
30. STOREK J, DAWSON MA, STORER B et al: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 97:3380-3389.
31. MARGOLIN K, FORMAN SJ: Immunotherapy with Interleukin-2 after haematopoietic cell transplantation for haematologic malignancies. Cancer J. Sci. Am. (2000) 6(Suppl. 1):33-38.
32. TOH HC, MCAFEE SL, SACKSTEIN R et al: A Phase II Study of high dose Cyclophosphamide + Carboplatin and Interleukin-2 activated autologous peripheral blood stem cell transplantation followed by subcutaneous IL-2 therapy in metastatic breast carcinoma. Bone Marrow Transplan. (2000) 25:19-24.
33. MEEHAN KR, ARUN B, GEHAN EA et al: Immunotherapy with Interleukin 2 and alpha-Interferon after IL-2 activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant. (1999) 23:667-673.
34. MITTAL P, CORTEGUERA B, ZHANG Y, GEHAN E, MEEHAN KR: Post transplant immunotherapy may improve long term survival in breast cancer patients. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 52.
35. HOLMBERG LA, OPARIN DV, GOOLEY T et al: Clinical outcome of breast and ovarian cancer patients with high doe chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. (2000) 25:1233-1241.
36. REECE DE, FOON KA, BHATTACHARYA-CHATTERJEE M et al: Use of the anti-idiotype antibody vaccine Triab after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transpl (2000) 26:729-735.
37. REECE DE, FOON K, CHATTERJE M et al: Vaccination with triab in conjunction with intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 388.
38. BASHEY A, CORRINGHAM S, LAW P et al: A Phase II Study of active specific immunotherapy with recombinant Mucin Peptide (MUC-1) after high dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 190.
39. HEMPEL D, MULLER P, ORUZIO D et al: Treatment of breast cancer with high dose chemotherapy followed by consolidation with monoclonal antibody 17/1 A. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 481.
40. REID DC: Dendritic cells and immunotherapy for malignant disease. Br. J. Haematol. (2001) 112:874-887.
41. SHURIN MR, LU L, KALINSKI P, STEWART-AKERS AM, LOTZE MT Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol (1999) 21:339-359.
42. AVIGAN D, WU Z, JOYCE R et al.: Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. (2000) 26:169-176.
43. ROULEAU M, SENIK A, LEROY E, VERNANT JP: Long term persistence of transferred PPD-reactive T-cells after allogeneic bone marrow transplantation. Transplantation (1993) 55:72-76.
44. BORRELLO I, SOTOMAYOR EM, RATTIS FM, COOKE SK, GU L, LEVITSKY HI: Sustaining the graft versus tumor effect through posttransplant immunization with granulocyte-macrophage-colony-stimulating factor (GM-CSF) producing tumor vaccines. Blood (2000) 95:3011-3019.
45. TALMADGE JE, REED E, INO K et al.: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. (1997) 19:161-172.
46. GALY A, RUDRARAJU S, BAYNES R, KLEIN J: Recovery of lymphocyte and dendritic cells subsets after autologous CD34+cell transplantation. Bone Marrow Transplan. (2000) 25:1249-1255.
47. WELTE K, CIOBANU N, MOORE MA, GULATI S, O'REILLY RJ, MERTELSMANN R: Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood (1984) 64:380-385.
48. AGEITOS AG, SINGH RK, INO K et al: IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products:monocyte inhibition. J. Immunother (1998) 21:409-417.
49. TALMADGE JE, SINGH R, INO K, AGEITOS A, BUYUKBERBER S: Mechanisms of immune dysfunction in stem cell transplantation. Int. J. Immunopharmacol (2000) 22:1041-1056.
50. SINGH RK, INO K, VARNEY ML, HEIMANN DG, TALMADGE JE: Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transpl. (1999) 23:53-62.
51. ARPINATI M, GREEN CL, HEIMFELD S, HEUSER JE, ANASETTI C: Granulocyte-colony stimulating factor mobilizes T helper 2 inducing dendritic cells. Blood (2000) 95:2482-2483.
52. TANAKA J, MIELCAREK M, TOROK-STORB B: Impaired induction of the CD 28-responsive complex in granulocyte-stimulating factor mobilized CD4 Tcells. Blood (1998) 91:347-352.
53. MIELCAREK M, GRAF L, JOHNSON G, TOROK-STORB B: Production of Interleukin-10 by granulocyte colony stimulating factor mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood (1998) 92:215-222.
54. MEEHAN KR WUA, HASSAN R et al: Ex vivo activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. J. Hematother Stem Cell Res. (2001) 10:283-290.
55. WALDMANN TA, DUBOIS S, TAGAYA Y Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity (2001) 14:105-110.
56. HINTERBERGER-FISCHER M, OGRIS E, KIER P et al: Elevation of plasma prolactin in patients undergoing autologous blood stem cell transplantation for breast cancer: is its modulation a step towards posttransplant immunotherapy? Am. J. Clin. Oncol. (2000) 23:325-329.
57. FERRARA JLM, ANTIN JH: The Pathophysiology of graft versus host disease. In: Haematopoetic cell transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):305-315.
58. DREGER P, SCHMITZ N: Allogeneic transplantation of blood stem cells: coming of age? Ann. Hematol (2001) 80:127-136.
59. POWELS R, MEHTA J, KULKARNI S et al: Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomized trial. Lancet (2000) 355:1231-1237.
60. BENSINGER WI, STORB R: Allogeneic peripheral blood stem cell transplantation. Rev. Clin. Exp. Hematol. (2001) 5:67-86.
61. PAN L, DELMONTE J Jr., JALONEN CK, FERRARA JL: Pretreatment of donor mice with granulocyte colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus host disease. Blood (1995) 86:4422-4429.
62. MILLER JS, PROSPER F, MC CULLAR V: Natural killer cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony stimulating factor mobilized blood progenitor cell collections. Blood (1997) 90:3098-3105.
63. REDDY V, HILL GR, PAN L et al.: G-CSF modulates cytokine profile of dendritic cells and decreases acute graft versus host disease through effects on the donor rather than the recipient. Transplantation (2000) 69:691-693.
64. PORRATA LF, INGLE JN, LITZOW MR, GEYER SM, MARKOVIC SN: Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 33.
65. GASTL G, MARTH C, LEITER E et al: Effects of human recombinant alpha 2arg-interferon and gamma interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res. (1985) 45:2957-2961.
66. O'GARRA A: Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity (1998) 8:275-283.
67. YOUNG JM: Immunotherapeutic applications of dendritic cells. Hematology 2000. American Society of Hematology Education Program Book. San Francisco (2000) :361-366.
68. DINARELLO CA: Interleukin-18. Methods (1999) 19:121-132.
69. MATERA L, MORI M, GEUNA M, BUTTIGLIERI S, PALESTRO G: Prolactin in autoimmunity and antitumor defence. J. Neuroimmunol (2000) 109:47-55.
70. BURNS LJ, WEISDORF DJ, DEFOR TE et al: Enhancement of anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin-2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol (2000) 28:96-103.
71. SOSMAN JA, STIFF P, MOSS SM et al.: Pilot trial of Interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high dose chemotherapy: expansion of immune effectors within the stem cell graft and post stem cell infusion. J. Clin. Oncol. (2001)19:634-644.
72. MEEHAN KR, VERMA UN, CAHILL R et al.: Interleukin 2 activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. Bone Marrow Transplant. (1997) 20:643-651.
73. MILLER JS, TESSMER-TUCK, PIERSON BA et al: Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol. Blood Marrow Transplant. (1997) 3:34-44.
74. LOPEZ-JIMINEZ J, PEREZ-OTEYZA J, MUNOZ A et al: Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non randomized study. Bone Marrow Transplant. (1997) 19:429-434.
75. GRAVIS G,VIENS P, VEY N et al: Pilot study of immunotherapy with interleukin 2 after autologous stem cell transplantation in advanced breast cancer. Anticancer Res. (2000) 20:3987-3991.
76. VIVANCOS P, GRANENA A Jr., SARRA J, GRANENA A: Treatment with interleukin-2 and Interferon-alpha 2b after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant. (1999) 23:169-172.
77. BACHIER CR, LANZKRON M, HOUGHAM M et al: Interleukin-2 and granulocyte macrophage colony stimulating factor for immune activation following autologous stem cell transplant increase lymphocyte subsets more than either drug alone. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 233.
78. LI XC, DEMICRI G,FERRARI-LACRAZ et al: IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. (2001) 7:114-118.
79. KRUMENACKER JS, BUCKLEY DF LEFF MA et al.: Prolactin regulated apoptosis of Nb2 lymphoma cells: pim-1, Bcl-2 and bax expression. Endocrine (1998) 9:163-170.
80. MATERA L, CONTARINI M, BELLONE G, FORNO B, BIGLINO A: Up-modulation of interferon-γ mediates the enhancement of spontaneous cytotoxicity in prolactin activated natural killer cells. Immunology (1999) 98:386-392.
81. NAGLER A, ACKERSTEIN A, OR E, NAPARSTEK E,SLAVIN S: Immunotherapy with recombinant human interleukin 2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood (1997) 89:3951-3959.
82. VEY N, VIENS P, FOSSAT C et al.: Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin 2 after autologous bone marrow transplantation. Euro. Cytokine Network (1997) 8:389-394.
83. HEHLMANN R, HOCHHAUS A, BERGER U, REITER A: Current trends in the management of chronic myelogenous leukemia. Ann. Hematol. (2000) 79:345-354.
84. BYKOVSKAIA SN, BUFFO M, ZHANG H et al.: The generation of human dendritic and NK cells from hemopoetic progenitors induced by interleukin 15. J. Leukoc. Biol. (1999) 66:659-666.
85. COOPER MA, FEHNINGER TA, TURNER SC et al.: Human natural killer cells: a unique innate immunoregulatory role for the CD 56 bri ght subset. Blood (2001) 97:3146-3151.
86. MATERA L: Minireview: endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. (1996) 59:599-614.
87. FERRAG F, GOFFIN V, BUTEAU H, KELLY PA: Immune function of prolactin and signal transduction by PRL/GH cytokine receptors: specificity, redundancy and lessons from chimaeras. Cytokin. Cell Mol. Ther. (1997) 3:197-213.
88. WOODY MA, WELNIAK LA, RICHARDS S et al.: Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmunomodulation (1999) 6:69-80.
89. LETTERIO JJ, ROBERTS AB: Regulation of immune responses by TGF-β. Annu. Rev. Immunol. (1998) 16:137-161.
90. PARIHAR R, NADELLA P, JENSEN R, DIERKSHEIDE J, SHAPIRO C, CARSON W: A Phase I trial of Herceptin and Interleukin 12 in patients with HER-2/neu overexpressing malignancies. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1031.
91. STEINBRINK K, JONULEIT H, MULLER G et al: Interleukin-10 treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+Tcells resulting in failure to lyse tumor cells. Blood (1999) 93:1634-1642.
92. MORSE MA, MOSCA PJ, HOBEIKA A et al.: Immunotherapy with Flt3-Ligand mobilized dendritic cells loaded with carcinoembryonic antigen peptide in patients with metastatic malignancies expressing CEA. 36th anNual Meeting of the American Society of Oncology (ASCO), (2000). Abstract 1840.
93. MENETRIER-CAUX C, THOMACHOT MC, ALBERTI L, MONTMAIN G, BLAY JY: IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. (2001) 61:3096-3104.
94. NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. (2001) 12:53-72.
95. DE MAGALHAES-SILVERMAN M, DONNENBERG A, LEMBERSKY B et al: Post-transplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J. Immunother (2000)23:154-160.
96. WOOD GW, DANSEY RD, KLEIN JL et al.: Combined modality high dose chemotherapy followed by adoptive immunotherapy to eliminate minimal residual disease in metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 390.
97. BRENNER M, ROSSIG C, SILI U: Virus and tumor specific cytotoxic T cell therapy. Hematology 2000. American Society of Hematology Education Program Book. San Francisco (2000) :356-360.
98. GRIBBEN JG: Antibody-mediated purging. In: Hematopoetic Cell Transplana tion. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science (1999):207-216.
99. COLVIN OM: Pharmacological purging of bone marrow. In: Hematopoetic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):217-224.
100. JOHNSEN HE, HUTCHINGS M, TAANING E et al.: Selective loss of progenitor subsets following CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation. Bone Marrow Transplant. (1999) 24:1329-1336.
101. MOHR M, HILGENFELD E, FIETZ T et al.: Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high dose therapy. Clin. Cancer Res. (1999) 5:1035-1040.
102. HUANG Y, YANG J, WANG XB, BECKER FF, GASCOYNE PR: The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretric field-flow-fraction. J. Hematother. Stem Cell Res. (1999) 8:481-490.
103. HIRAI M, KELSEY LS, VAILLANCOURT M, MANEVAL DC, WATANABE T, TALMADGE JE : Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. Cancer Gene Ther. (2000) 7:197-206.
104. WU A, MAZUMDER A, MARTUZA RL et al.: Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. (2001) 61:3009-3015.
105. SPYRIDONIDIS A, BERNHARDT W, BEHRINGER D et al.: Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD 34+ blood progenitor cells. Blood (1999) 93:746-755.
106. BRASSEUR N. MENARD I, FORGET A et al.: Eradication of multiple myeloma and breast cancer cells by TH9402 mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem. Photobiol. (2000) 72:780-787.
107. WILLIAMS SF, RIZZO D, WU J, ANTMAN K, HOROWITZ M: Syngeneic stem cell transplantation in metastatic breast cancer. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 2018.
108. WHITE C, WEAVER R, GRILLO-LOPEZ A: Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. (2000) 52:125-145.
109. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17:2639.
110. RHA SY, TOLCHER AW, STEPHENSON J et al: A Phase I study of Brevarex, a murine monoclonal antibody directed at the MUC1 antigen in patients with advanced solid tumors. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 1868.
111. SLAMON DJ, LEYLAND JONES B, SHAK S et al: Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N. Engl. J. Med. (2001) 344:783-792.
112. MANGEL J, BUCKSTEIN R, IMRIE K et al: Combined autologous stem cell transplantation and immunotherapy with rituxan in patients with newly diagnosed mantle cell lymphoma. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 2670.
113. ILLIDGE TM, BROCK S: Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm. Des. (2000) 6:1399-1418.
114. RICHMAN CM, DE NARDO SJ, O'DONNELL et al: Dosimetry based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin-A. Clin. Cancer Res. (1999) 5(Suppl. 10):3243s-3248s.
115. VOSE JM, BIERMAN PJ, LYNCH JC et al: Radioimmunotherapy with Bexxar combined with high dose chemotherapy followed by autologous hematopoietic stem cell transplantation for refractory non-Hodgkin's lymphoma: synergistic results with no added toxicity. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 19.
116. MURRAY JL: Monoclonal antibody treatment of solid tumors: a coming of age. Semin. Oncol. (2000) 27(6 Suppl. 11):64-70 Discussion 92-100.
117. BROWN RE, BERNATH AM, LEWIS GO: HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. Ann. Clin. Lab. Sci. (2000) 30:249-258.
118. RICHARDS SM, GARMAN RD, KEYES L, KAVANAGH B, MC PHERSON JM: Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cell Immunol (1998) 184:85-91.
119. REPP R, VAN OJIK H, VALERIUS TH et al: Phase I trial of bispecific antibody MDX-H210 ( Fcy RI X HER-2/neu) up to high doses in combination with G-CSF in patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 1865.
120. REILLY RT, MACHIELS JP, EMENS LA et al.: The collaboration of both humoral and cellular HER-2/neu targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. (2001) 61:880-883.
121. SCANLAN MJ: Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. (2001) 3:95-98.
122. BOCCIA M, BRONTE V, COLOMBO MP et al.: Antitumor Vaccination: where we stand. Haematologica (2000) 85:1172-1206.
123. JIANG XP, YANG DC, ELLIOTT RL, HEAD JF: Vaccination with a mixed vaccine of autologenous and allogeneic breast cancer cells and tumor associated antigens CA15-3,CEA and CA125 results in immune and clinical responses in breast cancer patients. Cancer Biother. Radiopharm. (2000) 15:495-505.
124. BHATTACHARAYA-CHATTERJEE M, CHATTERJEE SK, FOON KA: The antiidiotype vaccines for immunotherapy. Curr. Opin. Mol Ther. (2001) 3:63-69.
125. KNUTSON KL, SCHIFFMAN K, DISIS ML: Immunization with a HER2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J. Clin. Invest. (2001) 107:477-484.
126. DOEHN C, JOCHAM D: Technology evaluation: TG-1031, transgene SA. Curr. Opin. Mol. Ther. (2000) 2:106-111.
127. SCHOLL SM, BALLOUL JM, LE GOC G et al.: Recombinant vaccinia virus encoding human MUC1 and IL-2 as immunotherapy in patients with breast cancer. J. Immunother. (2000) 23:570-580.
128. MORSE MA, DENG Y, COLEMAN D et al.: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1) pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. (1999) 5:1331-1338.
129. BRAUN SE, CHEN K, FOSTER RG et al.: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. (2000) 164:4025-4031.
130. BRAUN SE, CHEN K, BLAZAR P et al.: Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony stimulating factor and a potential mechanism, of action. Hum. Gene Ther. (1999) 10:2141.
131. DE ZOETEN EF, CARR-BRENDEL V, MARKOVIC D, TAYLOR-PAPADIMITROU J, COHEN EP: Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. J. Immunol. (1999) 162:6934-6941.
132. COHEN EP: DNA-based vaccines for the treatment of cancer-an experimental model. Trends Mol. Med. (2001) 7:175-179.
133. MORSE MA: Technology evaluation: Theratope, Biomira Inc. Curr. Opin. Mol. Ther. (2000) 2:453-458.
134. KIM SH, CAREW JF, KOOBY DA et al.: Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single cycle herpes virus in squamous cell cancer. Cancer Gene Ther. (2000) 7:1279-1285.
135. DILLMAN RO, WIEMANN M, NAYAK SK et al.: Interferon gamma or granulocyte macrophage colony stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short term cell line cultures: a randomized phase II trial of the cancer biotherapy research group. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1092.
136. SONG K, CHANG Y, PRUD'HOMME GJ: IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther. (2000) 7:1527-1535.
137. CAMPBELL I, MAGLIOCCO A, MOYANA T, ZHENG C, XIANG J: Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther. (2000) 7:1270-1278.
138. MAJUMDAR AS, ZOLOTOREV A, SAMUEL S et al.: Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. (2000) 7:1086-1099.
139. HOOD AF, VOGELSANG GB, BLACK LP et al.: Acute graft versus host disease: development following autologous and syngeneic bone marrow transplantation. Arch. Dermatol. (1987) 123:745-750.
140. SICA S, CHIUSOLO P, SALUTARI P et al.: Autologous graft versus host disease after CD34+ purified autologous peripheral blood progenitor cell transplantation. J. Hematother. Stem Cell Res. (2000) 9:375-379.
141. HESS AD, JONES RJ: Autologous graft versus host disease. In: Hematopoietic Cell Transplantation' (Edition 2). Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):342-348.
142. KENNEDY MJ, VOGELSANG GB, JONES RJ et al.: Phase I trial of interferon gamma to potentiate cyclosporine induced graft versus host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. (1994) 12:249-257.
143. VOGELSANG GB, BITTON RJ, PIANTADOSI S et al.: Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant. (1999) 24:637-640.
144. BARON F, GOHOT A, SALMON JP et al.: Clinical course and predictive factors for cyclosporine-induced autologous graft versus host disease after autologous haematopoietic stem cell transplantation. Br. J. Haematol. (2000) 111:745-753.
145. MARIN GH, PORTO A, PRATES V et al.: Graft versus host disease in autologous stem cell transplantation. J. Exp. Clin. Cancer Res. (1999) 18:201-208.
146. HIESTAND PC, MEKLER P, NORDMANN R, GRIEDER A, PERMMONGKOL CH: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc. Natl. Acad. Sci. USA (1986) 83:2599-2603.
147. RECCHIA F, DEFILIPPIS S, ROSSELLI M et al.: Phase II study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced cancer. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1053.
148. KIANG DT, PAN W, KOLLANDER R, YANG J, KENNEDY BJ: Modulation of HER2 oncogene by ALL-trans-retinoic acid via AP-2 transcription factor in human breast cancer cells. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1683.
149. GIACCONE G, PUNT C, ANDO Y et al.: KRN7000, an NKT cell enhancer, in patients with solid tumours-a Phase I study of EORTC BTDG. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 1871.
150. VREDENBURGH J, LONG G BLACKWELL K et al: Thalidomide modulates vascular endothelial growth factor (VEGF) levels post autologous peripheral blood progenitor cell transplantation in patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 599.
151. BAIDAS SM, WINER EP, FLEMING GF et al: Phase II evaluation of thalidomide
152. GABRILOVICH DI, CHEN HL, GIRGIS KR et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2:1096-1103.
153. NATHAN PD, WALKER D, BRIDLE H et al: A phase II study investigating the use of thalidomide in conjunction with interferon-OC in patients with metastatic renal cell carcinoma. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1058.
154. HATTOREI K, HIRANO T, OSHIMI K, YAGITA H, OKUMURA K: A metalloproteinase inhibitor prevents acute graft versus host disease while preserving the graft versus leukaemia effect of allogeneic bone marrow transplantation. Leuk. Lymphoma (2000) 38:553-561.
155. RINGDEN, PABOPIN M, GORIN NC et al: Is there a graft versus leukaemia effect in the absence of graft versus host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br. J. Haematol. (2000) 111:1130-1137.
156. SOIFFER RJ, MURRAY C, GONIN R et al: Effect of low dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation. Blood (1994) 84:964-971.
157. ROBINSON N, SANDERS JE, BENYUNES MC et al: Phase I trial of IL-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood (1996) 87:1249-1254.
158. DAZZI F, GOLDMAN J: Donor lymhocyte infusions. Curr Opin. Hematol (1999) 6:394-399.
159. MACKINNON S: Donor leukocyte infusions. Baillieres Clin. Haematol. (1997) 10:357-367.
160. SLAVIN S, NAPARSTEK E, NAGLER A et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87:2195-2204.
161. LAWS HJ, NURNBERGER W, KORHOLZ D et al: Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFN-alpha. Bone Marrow Transplan. (2000) 25 (2) :219-222.
162. LEDA M, LADON D, PIECZONKA A et al: Donor lymphocyte infusion followed by interferon-alp ha plus low dose cyclosporine A for modulation of donor CD 3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk. Res. (2001) 25:353-357.
163. FLOWERS ME, LEISENRING W, BEACH K et al: Granulocyte colony stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with conor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol. Blood Marrow Transplan. (2000) 6(3A):321-326.
164. WALLER EK, BOYER M: New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T-cells Bone Marrow Transplant. (2000) 25(Suppl. 2):S20-S24.
165. MARTINO R, MARTIN-HENAO G, SURADA A et al: Allogeneic peripheral blood stem cell transplantation with CD 34+ cell selection and delayed T cell add back in adults. Result of a single center pilot study. Haematologica (2000) 85:1165-1171.
166. CORNELISSEN JJ, LOWENBERG B: Developments in T-cell depletion of allogeneic stem cell grafts. Curr. Opin. Hematol. (2000) 7:348-353.
167. FOWLER DH, GRESS RE: Th2 and Tc2 cells in the regulation of GVHD, GVL and graft rejection: considerations for the allogeneic transplantation therapy of leukaemia and lymphoma. Leuk. Lymphoma (2000) 38:221-234.
168. BLAZAR BR, KWON BS, PANOSKALTSIS-MORTARI A, KWAK KB, PESCHON JJ, TAYLOR PA: Ligation of 4-1BB (CDw137) regulates graft versus host disease graft versus leukaemia and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. (2001) 166:3174-3183.
169. GOKER H, HAZNEDAROGLU IC, CHAO NJ: Acute graft versus host disease: pathobiology and management. Exp. Hematol. (2001) 29:259-277.
170. EIBL B, SCHWAIGHOFER H, NACHBAUR D: Evidence for a graft versus tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 88:1501-1508.
171. BAY JO, CHOUFI B, POMEL C et al: Potential allogeneic graft versus tumor effect in a patients with ovarian cancer. Bone Marrow Transplant. (2000) 25:681-682.
172. CHILDS R, CHERNOFF A, CONTENTIN N et al: Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl. J. Med. (2000) 343:750-758.
173. LIMA M, BONAMINO M, VASCONCELOS Z et al: Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft versus host disease. Bone Marrow Transplan. (2001) 27:73-78.
174. BARRETT AJ: Conditioning regimen for allogeneic stem cell transplants. Curr. Opin. Haematol. (2000) 7:339-342.
175. ANDERSON LD Jr., MORI S, MANN S, SAVARY CA, MULLEN CA: Pretransplant tumor antigen specific immunization of allogeneic bone marrow transplant donors enhances graft versus tumor activity without exacerbation of graft versus host disease. Cancer Res. (2000) 60:5797-5802.
176. MORECKI S, YACOVLEV E, GELFAND Y, UZI I, SLAVIN S: Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J. Immunother. (2001) 24:114-121.
177. ANDERSON LD Jr., SAVARY CA, MULLEN CA: Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft versus tumor activity without exacerbating graft versus host disease. Blood (2000) 95:2426-2433.
178. TESHIMA T, MACH N, HILL GR et al.: Tumor vaccine elicits potent antitumor immunity after allogeneic T-cell depleted bone marrow transplantation. Cancer Res. (2001) 61:162-171.
179. CHOI D, PERRIN M, HOFFMANN S et al.: Dendritic cell based vaccines in the setting of stem cell transplantation: CD34+ cell depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin. Cancer Res. (1998) 4:2709-2716.
180. WITTIG B, MARTEN A, DORBIC T et al.: Therapeutic vaccination against metastatic carcinoma by expression modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum. Gene Ther. (2001) 12:267-278.
181. GOLDBERG SL, PECORA AL, ROSENBLUTH RJ, JENNIS AA, PRETI RA: Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft versus leukaemia and graft versus host effects with cytokines. Bone Marrow Transplant. (2000) 26:353-355.